Monoclonal antibody ABX-RB2

Drug Profile

Monoclonal antibody ABX-RB2

Alternative Names: ABX-RB2

Latest Information Update: 24 Apr 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abgenix
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Autoimmune disorders; Transplant rejection

Most Recent Events

  • 16 Aug 2000 Abgenix and SangStat sign an antibody therapy agreement
  • 14 Apr 1999 Preclinical development for Autoimmune disorders in USA (Unknown route)
  • 14 Apr 1999 Preclinical development for Transplant rejection in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top